dc.contributor.author
Blazquez‐Navarro, Arturo
dc.contributor.author
Dang‐Heine, Chantip
dc.contributor.author
Wehler, Patrizia
dc.contributor.author
Roch, Toralf
dc.contributor.author
Bauer, Chris
dc.contributor.author
Neumann, Sindy
dc.contributor.author
Blazquez‐Navarro, Rodrigo
dc.contributor.author
Kurchenko, Andriy
dc.contributor.author
Wolk, Kerstin
dc.contributor.author
Sabat, Robert
dc.contributor.author
Westhoff, Timm H.
dc.contributor.author
Olek, Sven
dc.contributor.author
Thomusch, Oliver
dc.contributor.author
Seitz, Harald
dc.contributor.author
Reinke, Petra
dc.contributor.author
Hugo, Christian
dc.contributor.author
Sawitzki, Birgit
dc.contributor.author
Or‐Guil, Michal
dc.contributor.author
Babel, Nina
dc.date.accessioned
2022-12-02T13:53:03Z
dc.date.available
2022-12-02T13:53:03Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/37150
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-36863
dc.description.abstract
Epstein-Barr virus (EBV) reactivation is a very common and potentially lethal complication of renal transplantation. However, its risk factors and effects on transplant outcome are not well known. Here, we have analysed a large, multi-centre cohort (N = 512) in which 18.4% of the patients experienced EBV reactivation during the first post-transplant year. The patients were characterized pre-transplant and two weeks post-transplant by a multi-level biomarker panel. EBV reactivation was episodic for most patients, only 12 patients showed prolonged viraemia for over four months. Pre-transplant EBV shedding and male sex were associated with significantly increased incidence of post-transplant EBV reactivation. Importantly, we also identified a significant association of post-transplant EBV with acute rejection and with decreased haemoglobin levels. No further severe complications associated with EBV, either episodic or chronic, could be detected. Our data suggest that despite relatively frequent EBV reactivation, it had no association with serious complications during the first post-transplantation year. EBV shedding prior to transplantation could be employed as biomarkers for personalized immunosuppressive therapy. In summary, our results support the employed immunosuppressive regimes as relatively safe with regard to EBV. However, long-term studies are paramount to support these conclusions.
en
dc.rights.uri
https://creativecommons.org/licenses/by-nc/4.0/
dc.subject
EBV < Infection
en
dc.subject
Outcome < Kidney Clinical
en
dc.subject
Complications < Kidney Clinical
en
dc.subject
PTLD < Malignancies and long-term complications
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Risk factors for Epstein–Barr virus reactivation after renal transplantation: Results of a large, multi‐centre study
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.doi
10.1111/tri.13982
dcterms.bibliographicCitation.journaltitle
Transplant International
dcterms.bibliographicCitation.number
9
dcterms.bibliographicCitation.originalpublishername
Frontiers Media SA
dcterms.bibliographicCitation.pagestart
1680
dcterms.bibliographicCitation.pageend
1688
dcterms.bibliographicCitation.volume
34
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.funding
DEAL Wiley
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
34448272
dcterms.isPartOf.issn
0934-0874
dcterms.isPartOf.eissn
1432-2277